Advertisement

Antibody Induced Down Regulation of Membrane Receptors in Human Diseases

  • F. Clementi
  • E. Sher
Conference paper
Part of the NATO ASI Series book series (volume 6)

Abstract

During this meeting we have learned of several mechanisms that the cells put forward to cope with a large number of messages that reach their plasmamembrane. The most relevant is the desensitization of neurotransmitter receptors obtained by at least two mechanisms:
  1. 1)

    a change in the protein structure of the receptor by covalent modifications (methylation and phosphorylation, being the most important) resulting in an uncoupling of the receptors from the effector molecules or in a modification of ion channels characteristics.

     
  2. 2)

    a removal of the receptors from the cell membrane by internalization or by sequestration in the membrane itself.

     

Keywords

Insulin Receptor Neuromuscular Junction Nicotinic Receptor Receptor Internalization Acanthosis Nigricans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bottazzo, G.P., M.A. Drexhage, and E.L. Khoury (1982) In: Receptors, Antibodies and Disease. Evered O. and Whelan J., eds., Pitman Publ. Ltd, London, pp. 153–167.Google Scholar
  2. 2.
    De Pirro, R., R.A. Roth, L. Rossetti, I.D. Goldfine (1984) Diabetes 33: 301–304.PubMedCrossRefGoogle Scholar
  3. 3.
    Kahn, CR., M. Kasuga, G.L. King, C. Grunfeld (1982) In: Receptors, Antibodies and Disease. Evered O. and Whelan J., eds., Pitman Publ. Ltd, London, pp. 91–105.Google Scholar
  4. 4.
    Harrison, L.C., J.S. Flier, C.R. Khan (1979) J. Clin. Endocrinol. Metab. 48: 59–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Karlson, P.A., E. Van Obberghen, C Grunfeld, CR. Kahn (1979) Proc. Natl. Acad. Sci. USA 76: 809–813.CrossRefGoogle Scholar
  6. 6.
    Grunfeld, C., D.S. Jones, J.K Shigenaga (1985) Diabetes 34: 205–211.PubMedCrossRefGoogle Scholar
  7. 7.
    Zick, Y., R.W. Rees-Jones, S.I. Taylor, P. Gouden, J. Roth (1984) J. Biol. Chem. 259: 4396–4400.PubMedGoogle Scholar
  8. 8.
    Suppner, H., A.A. Bialasienicz, Merch R.O. (1978) Lancet 1222–1223.Google Scholar
  9. 9.
    Venter J.C., C.M. Praser, L.C. Harrison (1980) Science 207: 1361–1364.PubMedGoogle Scholar
  10. 10.
    Blecher M., S. Lewis, J.M. Nicks, S. Josephs (1984) J. Allergy Clin. Immunol. 74: 246-PubMedCrossRefGoogle Scholar
  11. 11.
    Praser, C.M., J.C. Venter, M. Kaliner (1981) New Engl. J. Med. 305: 1165-CrossRefGoogle Scholar
  12. 12.
    Harrison, L.C., J. Callaghan, J.C. Venter, C.M. Fraser, M.C. Kaliner (1982) In: Receptors, Antibodies and Disease. Evered O. and Whelan J., eds., Pitman Publ. Ltd, London, pp. 248–262.Google Scholar
  13. 13.
    Sher, E., P. Clementi (1985) Pharm. Res. Comm. 17: 1095–1106.CrossRefGoogle Scholar
  14. 14.
    Anderson, R.G.W., M.S. Brown, U. Beisiegel, J.L. Goldstein (1982) Cell Biol. 93: 523–531.CrossRefGoogle Scholar
  15. 15.
    Albuquerque, E.X., A.T. Eldefrawi (1983) Myasthenia Gravis, Chapman and Hall, New York.Google Scholar
  16. 16.
    Fambrough, D.M., D.B. Drachman, S. Satyamurti (1973) Science 182: 293–295.PubMedCrossRefGoogle Scholar
  17. 17.
    Toyka, K.V., D.B. Drachman, D.E. Griffin, et al. (1977) New. Engl. J. Med. 296: 125–131.PubMedCrossRefGoogle Scholar
  18. 18.
    Norcross, N.L., I.J. Griffith (1983) In: Myasthenia Gravis, Chapman and Hall, New York, pp. 347–389.Google Scholar
  19. 19.
    Keesey, J., J. Lindstrom, H. Lokely, C. Herrman (1977) New Engl. J. Med. 296: 55.PubMedGoogle Scholar
  20. 20.
    Lennon, V.A., M.E. Seybold, J.M. Lindstrom, L. Cochrane, R. Ulerit (1978) J. Exp. Med. 147: 973–983.PubMedCrossRefGoogle Scholar
  21. 21.
    Vincent, A. (1983) In: Myasthenia Gravis, Chapman and Hall, New York, pp. 297–317.Google Scholar
  22. 22.
    Kao, I., and D.B. Drachman (1977) Science 196:527–529.PubMedCrossRefGoogle Scholar
  23. 23.
    Heinemann, S., S. Bevan, R. Kuliberg, J. Lindstrom (1977) Proc. Natl. Acad. Sci. USA 74: 3090–3094.PubMedCrossRefGoogle Scholar
  24. 24.
    Conti-Tronconi, B.M., A. Brigonzi, G. Pumagalli, E. Sher, V. Cosi, L. Piccolo, P. Clementi (1981) Neurology 31: 1440–1444.Google Scholar
  25. 25.
    Drachman, D.B., R.N. Adams, L.P. Josifek, S.G. Seif (1982) New Engl. J. Med. 307: 769–775.PubMedCrossRefGoogle Scholar
  26. 26.
    Pumagalli, G., A.G. Engel, J. Lindstrom (1982) J. Neuropath. Exp. Neurol. 41: 567–579.CrossRefGoogle Scholar
  27. 27.
    Clementi, P., and E. Sher (1985) Eur. J. Cell Biol. 37: 220–228.PubMedGoogle Scholar
  28. 28.
    Sher, E., and F. Clementi (1984) Neurology 34: 208–211.PubMedGoogle Scholar
  29. 29.
    Clementi, P., E. Sher, A. Erroi (1983) Eur. J. Cell. Biol. 29: 274–280.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • F. Clementi
    • 1
  • E. Sher
    • 1
  1. 1.CNR Center of Cytopharmacology, Dept. of PharmacologyUniversity of MilanMilanoItaly

Personalised recommendations